XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Convertible Preferred Stock
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Additional Paid-In Capital
Accumulated Deficit
Class A Common Stock
Class B Common Stock
Total
Convertible Preferred Stock, Balance at beginning of the period at Dec. 31, 2020 $ 360,937              
Convertible Preferred Stock, Balance at beginning of the period (in shares) at Dec. 31, 2020 107,197,118              
Increase (Decrease) in Convertible Preferred Stock                
Conversion of convertible preferred stock $ (360,937)              
Conversion of convertible preferred stock (in shares) (107,197,118)              
Balance at beginning of the period at Dec. 31, 2020   $ 1   $ 32,874 $ (394,806)     $ (361,931)
Balance at beginning of the period (in shares) at Dec. 31, 2020   6,593,291            
Increase (Decrease) in Stockholders' Equity                
Net loss         (17,193)     (17,193)
Common stock issued upon exercise of stock options and warrants   $ 1   19,322       19,323
Common stock issued upon exercise of stock options and warrants (in shares)   8,268,869            
Common stock issued upon vesting of restricted stock units (in shares)   597,021            
Conversion of convertible preferred stock   $ 8 $ 3 360,926       360,937
Conversion of convertible preferred stock (in shares)   80,770,178 26,426,937          
Conversion of convertible debt   $ 1   49,916       49,917
Conversion of convertible debt (in shares)   5,115,140            
Net equity infusion from the Business Combination   $ 6   361,281       361,287
Net equity infusion from the Business Combination (in shares)   69,228,811            
Stock-based compensation expense       38,921       38,921
Balance at end of the period at Sep. 30, 2021   $ 17 $ 3 863,240 (411,999)     451,261
Balance at end of the period (in shares) at Sep. 30, 2021   170,573,310 26,426,937          
Balance at beginning of the period at Jun. 30, 2021   $ 17 $ 3 844,770 (398,438)     446,352
Balance at beginning of the period (in shares) at Jun. 30, 2021   167,477,126 26,426,937          
Increase (Decrease) in Stockholders' Equity                
Net loss         (13,561)     (13,561)
Common stock issued upon exercise of stock options and warrants       7,634       7,634
Common stock issued upon exercise of stock options and warrants (in shares)   2,966,397            
Common stock issued upon vesting of restricted stock units (in shares)   129,787            
Stock-based compensation expense       10,836       10,836
Balance at end of the period at Sep. 30, 2021   $ 17 $ 3 863,240 (411,999)     451,261
Balance at end of the period (in shares) at Sep. 30, 2021   170,573,310 26,426,937          
Balance at beginning of the period at Dec. 31, 2021   $ 17 $ 3 874,886 (427,215)     447,691
Balance at beginning of the period (in shares) at Dec. 31, 2021   171,613,049 26,426,937     171,613,049 26,426,937  
Increase (Decrease) in Stockholders' Equity                
Net loss         (135,020)     (135,020)
Common stock issued upon exercise of stock options and warrants       2,844       2,844
Common stock issued upon exercise of stock options and warrants (in shares)   1,035,574            
Common stock issued upon vesting of restricted stock units       (106)       (106)
Common stock issued upon vesting of restricted stock units (in shares)   1,425,979            
Stock-based compensation expense       28,228       28,228
Balance at end of the period at Sep. 30, 2022   $ 17 $ 3 905,852 (562,235)     343,637
Balance at end of the period (in shares) at Sep. 30, 2022   174,074,602 26,426,937     174,074,602 26,426,937  
Balance at beginning of the period at Jun. 30, 2022   $ 17 $ 3 894,162 (507,493)     386,689
Balance at beginning of the period (in shares) at Jun. 30, 2022   172,816,532 26,426,937          
Increase (Decrease) in Stockholders' Equity                
Net loss         (54,742)     (54,742)
Common stock issued upon exercise of stock options and warrants       2,034       2,034
Common stock issued upon exercise of stock options and warrants (in shares)   691,907            
Common stock issued upon vesting of restricted stock units (in shares)   566,163            
Stock-based compensation expense       9,656       9,656
Balance at end of the period at Sep. 30, 2022   $ 17 $ 3 $ 905,852 $ (562,235)     $ 343,637
Balance at end of the period (in shares) at Sep. 30, 2022   174,074,602 26,426,937     174,074,602 26,426,937